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Myopericarditis in a patient with recent Covid-19 mRNA vaccine
Zamran Masih DO, Dr. Wayne Tamaska DO, Nicholas Tomasello DO
Emergency Medicine Residency and Department of Emergency Medicine, Rowan University, SOM
Abstract:

Discussion:

Myopericarditis after covid-19 mRNA vaccination is not well
described. However, there have been several cases described
throughout the pandemic suggesting some correlation between covid19 vaccination and myopericarditis. We described such a case where
a patient developed myopericarditis after receiving Johnson &
Johnson vaccine.

Myopericarditis remains a rare side effect of Covid vaccination and number of cases
reflect that. A single center case series described eight cases of myopericarditis where
18,671 patients ages 16 to 25 received two doses of the Pfizer-BioNTech BNT162b2
(Pfizer) vaccine, 5,999 received two doses of the Moderna mRNA-1273 vaccine, and
three received a combination of the two. All eight patients that developed
myopericarditis were males and all received two doses of the Pfizer vaccine. All of the
patients presented with chest pain as the chief complaint which occurred within 3 days
after the second dose. All patients had elevated troponin levels and ST elevations on
EKG (Figure 1). All of the patients reported resolution of their symptoms and were
discharged after a short hospitalization. It is reassuring the fact that these eight cases
comprise 0.03% of the 24,673 individuals who received two doses of a COVID19 mRNA vaccine in the hospital system where the study was conducted.
Although our patient did not get any confirmatory imaging, there are certain findings on
cardiovascular magnetic resonance (CMR) imaging that can make a definitive
diagnosis of myopericarditis. In one such case of a teenager that developed
myopericarditis after the first dose of the Covid mRNA vaccine, CMR was used to make
the diagnosis. The CMR showed mild left ventricular systolic dysfunction, with elevated
myocardial T1 in the basal to mid-inferior and lateral segments, consistent with
myocardial fibrosis and edema, with corresponding sub-epicardial late gadolinium
enhancement and increased extracellular volume (Figure 2). As more and more young
people are getting vaccinated it is important to consider the small number of cases of
myopericarditis that appears to affect patients in the age range of 16 to 25. Fortunately,
the symptoms described appear to be mild and patients recover fully with great
prognosis (Fleming-Nouri A et al).
One possible proposed mechanism of vaccine induced myopericarditis is the
exaggerated levels of antibodies that mRNA vaccines can generate in young adults
and mRNA being a natural activator of the innate immune system and results in an
immune overreaction that can affect multiple organs, such as the heart (Michele Golino
et al).

Introduction:
Myopericarditis is a relatively rare condition and even more rare when it’s
secondary to a Covid—19 vaccine. In this case, we describe a patient with a
presumed diagnosis of myopericarditis shortly after receiving the covid-19
vaccine. She had two Emergency Department visits, and on the second visit was
admitted and worked up by cardiology after having elevated troponin levels.
Patient subsequently fully recovered with no known morbidity.
Case Presentation:
Patient is a 38 year old female with history of diabetes and asthma who presented to the
ED on 4/24/2021 with fever, chills, diffuse myalgias, headache, and sore throat. Patient
had been seen at an urgent care earlier in the week and had a negative Covid test and
viral bio fire. Patient reported getting the Johnson & Johnson on 4/7 and her symptoms
started on 4/16. The patient was febrile to 102.9 in the ED. She was also tachycardic
in the 120s and described the chest pain as positional and pleuritic. EKG was without
ischemic changes with elevated troponin. Patient’s initial troponin were 2,014, 3,415, and
peaked at 3,438. Patient was diagnosed with myocarditis. She was septic on admission
and started on IV antibiotics which were later discontinued. During this visit her Strep,
Flu, HIV, and EBV were negative. CMV was positive for IgG but no IgM. Parvovirus was
pending. Patient was evaluated by Cardiology and had a negative echocardiogram.
Patient’s pain improved with colchicine, NSAIDs, and Tramadol. Patient was deemed
stable and discharged on 4/28/2021.
Patient returned to the ED on April 29th with continued chest pain. Her troponins
continued to trend down with initial one being 93, 61, and 47. CTA PE study was negative
for pulmonary embolism. Patient was again evaluated by Cardiology. Further
investigation proved that patient started to have symptoms 24 hours after receiving the
Johnson & Johnson vaccine and has had it for over a month despite using NSAIDs.
Patient also had positive titers for Coxsackie virus. However, cardiology believed
patient’s symptoms combined with lab findings suggest the diagnosis of myopericarditis.
They believed the etiology is more involved than viral myocarditis. They believe the
vaccine, most likely, played a role in the development of the myopericarditis given the
proximity of the symptom development to the vaccine. Outpatient cardiac MRI was
recommended. Patient’s troponins and symptoms continued to improve and she was
discharged in a stable condition.

Figure 1

Conclusions:
We described a case of myopericarditis resulting presumably from a recent Covid-19
mRNA vaccine. Patient presented with chest pain, myalgias, and malaise. On labs
patient had markedly elevated troponin levels with no EKG changes. Patient recovered
fully with anti-inflammatory medications. Although, no CMR was done in our patient, the
findings of sub-epicardial late gadolinium enhancement point to a diagnosis of
myopericarditis (Daniel H Chen et al). Although there are several such reported cases,
vaccine induced myopericarditis still remains a rare diagnosis and benefits of protection
through vaccines far outweighs the small risk of myopericarditis.
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